Analysis of the Potential Topical Anti-Inflammatory Activity of Averrhoa carambola L. in Mice by Cabrini, Daniela Almeida et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 908059, 7 pages
doi:10.1093/ecam/neq026
Original Article
Analysisof the Potential Topical Anti-Inﬂammatory
Activity of Averrhoacarambola L. inMice
DanielaAlmeidaCabrini,1 Henrique Hunger Moresco,2 PriscilaImazu,1
C´ ıntiaDelaida Silva,1 EveliseFernandesPietrovski,1 DanielAugustoGasparin
Bueno Mendes,1 Arthur da Silveira Prudente,1 MoacirGeraldoPizzolatti,2 Inˆ es
Maria Costa Brighente,2 andMichelFleithOtuki3
1Laboratory of Inﬂammation, Department of Pharmacology, Universidade Federal do Paran´ a, Curitiba, PR, Brazil
2Department of Chemistry, Universidade Federal de Santa Catarina, Campus Universit´ ario, Trindade, Florian´ opolis, SC, Brazil
3Department of Pharmaceutical Sciences, Universidade Estadual de Ponta Grossa, Ponta Grossa, Campus Uvaranas,
Av. General Carlos Cavalcanti 4748, Bloco M, Sala 94, 84030-900, PR, Brazil
Correspondence should be addressed to Michel Fleith Otuki, michelotuki@yahoo.com.br
Received 15 October 2009; Accepted 8 March 2010
Copyright © 2011 Daniela Almeida Cabrini et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Inﬂammatory skin disorders, such as psoriasis and atopic dermatitis, are very common in the population; however, the treatments
currently available are not well tolerated and are often ineﬀective. Averrhoa carambola L. (Oxalidaceae) is an Asian tree that has
been used in traditional folk medicine in the treatment of several skin disorders. The present study evaluates the topical anti-
inﬂammatory eﬀects of the crude ethanolic extract of A. carambola leaves, its hexane, ethyl acetate, and butanol fractions and two
isolated ﬂavonoids on skin inﬂammation. Anti-inﬂammatory activity was measured using a croton oil-induced ear edema model
of inﬂammation in mice. Topically applied ethanolic extract reduced edema in a dose-dependent manner, resulting in a maximum
inhibition of 73 ± 3 %a n da nI D 50 value of 0.05 (range: 0.02–0.13) mg/ear. Myeloperoxidase (MPO) activity was also inhibited
by the extract, resulting in a maximum inhibition of 60 ± 6% (0.6 mg/ear). All of the fractions tested caused inhibition of edema
formation and of MPO activity. Treatment with the ethyl acetate fraction was the most eﬀective, resulting in inhibition levels of
75 ± 5a n d5 4± 8% for edema formation and MPO activity, respectively. However, treatment of mice with isolated compounds
[apigenin-6-C-β-l-fucopyranosideand apigenin-6-C-(2  -O-α-l-rhamnopyranosyl)-β-l-fucopyranoside]didnotyieldsuccessful
results. Apigenin-6-C-(2  -O-α-l-rhamnopyranosyl)-β-l-fucopyranoside caused only a mild reduction in edema formation (28 ±
11%). Taken together, these preliminary results support the popular use of A. carambola as an anti-inﬂammatory agent and open
up new possibilities for its use in skin disorders.
1.Introduction
The skin is an external organ that covers the entire body
surface. It is responsible for the communication between an
organism and the environment and is constantly subjected
to exogenous stimuli. The main function of the skin is to
protect the organism from environmental insults [1, 2].
Fulﬁlling its role, the skin is able to activate a defense
mechanism aimed at pathogen elimination and tissue repair
[3]. Initiation of the defense response is characterized by
the inﬁltration of neutrophils and the release of several
pro-inﬂammatory mediators, which starts the inﬂammatory
process. If this inﬂammatory response is not appropriately
regulated, an inﬂammatory skin disease can be triggered
[4]. The most common inﬂammatory skin disorders include
atopic dermatitis and psoriasis. Both of these disorders can
have a high impact on the patient’s quality of life, and
the treatments for these diseases are usually not eﬀective
[5–7]. Because currently available therapeutics to treat
chronic inﬂammatory skin diseases are mostly ineﬀective
and produce a plethora of side eﬀects, the search for
more eﬀective and safer treatment alternatives is necessary.
Natural products derived from plants have long been used
in folk medicine, making the compounds derived from
these plants good candidates for new therapeutic strategies
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Averrhoa carambola L. (Oxalidaceae) is an Asian tree that
was introduced to Brazil. This tree is also known as the star
fruittreeandiscommonlyusedtotreatheadaches,vomiting,
coughing and hangovers [11]. Furthermore, it is used as an
appetite stimulant, a diuretic, and as an antidiarrheal and
febrifugal agent. A. carambola has been used in the treatment
of eczemas [12]. In addition, the extract obtained through
decocting the leaves of A. carambola has been used in the
treatment of diabetes [13].
Phytochemistry studies have shown that the fruit of A.
carambola is rich in antioxidants, especially polyphenolic
compounds, which act against reactive oxygen species.
Investigationscharacterizingthesecondarymetabolitesof A.
carambola have identiﬁed two O-glycosyl ﬂavonoid compo-
nents: quercetin-3-O-β-d-glucoside and rutin [14]. Other
compounds indentiﬁed included the following: β-sitosterol,
lupeol, anthraquinone glucoside [15], cyanidin-3-O-β-d-
glucoside, cyanidin-3,5-O-β-d-diglucoside [16], β-amirin
[17], and C-glycoside ﬂavones, such as apigenin-6-C-β-
l-fucopyranoside and apigenin-6-C-(2
  -O-α-l-rhamnopy-
ranosyl)-β-l-fucopyranoside. This latter compound is also
known as carambolaﬂavone [18].
Furthermore, the insoluble ﬁbers of the star fruit slow
theabsorptionofcarbohydrates,signiﬁcantlyreducingblood
glucoselevels.Theﬁbercanalsoacttopreventcardiovascular
disease by reducing serum triglyceride and total cholesterol
levels [19–21]. Lastly, selective activity against brain tumor
cells was observed with an alcoholic extract from the stems
ofA.carambola,whileanextractfromtheleaveswaseﬀective
against liver carcinoma cells [17].
In the present study, we investigated the potential anti-
inﬂammatory properties of the leaves from this plant. For
these studies, the topical anti-inﬂammatory activity of the
ethanolic extract and two isolated ﬂavonoids from the leaves
of A. carambola w e r ee v a l u a t e do nac l a s s i cm o d e lo fs k i n
inﬂammation—croton oil-induced mouse ear edema.
2. Methods
2.1.ExtractionandIsolation. TheleavesofA.carambolawere
collected in March 2003 at Santo Amaro da Imperatriz in
Santa Catarina, Brazil, and identiﬁed by botanist Daniel de
Barcellos Falkenberg. A voucher specimen (FLOR 24.144)
was deposited in the Herbarium FLOR, Universidade Federal
de Santa Catarina, Santa Catarina, Brazil.
The air-dried leaves of A. carambola (281g) were ex-
tracted with 80% ethanol at room temperature for 15
days. The solvent was removed by rotary evaporation (at
<55◦C). The ethanolic extract (41.3g) was resuspended
in 80% (v/v) ethanol and partitioned with hexane (Hex),
ethyl acetate (EtOAc) and n-butanol (n-BuOH). The EtOAc
fraction (6.9g) was run on a silica gel-based chromatog-
raphy column and was eluted with mixtures of various
ratios of Hex, EtOAc, and ethanol to yield the ﬂavonoids,
apigenin-6-C-β-l-fucopyranoside (150mg) (compound 1)
and apigenin-6-C-(-2
  -O-α-l-rhamnopyranosyl)-β-l-fuco-
pyranoside (200mg) (compound 2). Identiﬁcation of the
ﬂavonoidswascarriedoutusingspectralidentiﬁcationmeth-
ods (1H NMR, 1H–1H COSY, 13C NMR, DEPT, HMQC,
HMBC) and by comparing these data with those reported
in the literature [22, 23].
2.2. Animals. Experiments were performed on Swiss male
mice (25–35g) housed at 22 ± 2◦C under a 12-h light/12-h
dark cycle, with free access to food and water. Experiments
were performed during the light phase of the cycle. The
animals were allowed to adapt to the laboratory for at least
1h before testing and were used only once. The experiments
reported in this study were carried out in accordance with
guidelines speciﬁed by the Ethics Committee on Animal
Experimentation of the Federal University of Paran´ aa n da r e
in accordance with international guidelines.
2.3. Ear Edema Measurements. Edema was quantiﬁed by
the increase in ear thickness of mice upon inﬂammatory
challenge. Ear thickness was measured before and after
induction of the inﬂammatory response using a digital
micrometer (Great, MT-045B). The micrometer was applied
near the tip of the ear just distal to the cartilaginous ridges,
and the thickness was recorded in micrometers. To mini-
mize technique variations, a single investigator performed
the measurements throughout each experiment [24]. The
phlogistic agents, the ethanolic extract and its fractions and
compounds were dissolved in 20 μLo fa c e t o n ea n da p p l i e d
to the right ear of each mouse.
2.4. Croton-Oil-Induced Ear Edema. Edema was induced in
the right ear by topical application of croton oil at a con-
centration of 0.4mg/ear. Hex, EtOAc and BuOH fractions of
the ethanolic extract, compounds 1 and 2 from A. caram-
bola, and dexamethasone (DE) (a positive control) were
applied topically immediately after croton oil treatment. Ear
thickness was measured prior to and 6h after the induction
of inﬂammation. Ear samples (circles of tissue 6mm in
diameter) were collected 24h after the application of croton
oil and were measured for myeloperoxidase (MPO) activity.
2.5. Tissue MPO Activity Assay. The activity of tissue MPO
wasassessed24haftercrotonoilapplicationtothemouseear
according to the technique reported by Suzuki et al. [25]a n d
modiﬁed by De Young et al. [26]. A biopsy (6mm ear tissue
punch) was placed in 0.75mL of 80mM phosphate-buﬀered
saline (PBS), pH 5.4 containing 0.5% hexadecyltrimethy-
lammonium bromide and homogenized (45s at 0◦C) in a
motor-driven homogenizer. The homogenate was decanted
into a microfuge tube, and the vessel was washed with
a second 0.75mL aliquot of hexadecyltrimethylammonium
bromide in buﬀer. The wash was added to the tube, and
the 1.5mL sample was centrifuged at 12000g at 4◦Cf o r
15min. Samples of the resulting supernatant were added
to 96-well microlitre plates in triplicate at a volume of
30μL. For the MPO assay, 200μL of a mixture containing
100μL of 80mM PBS pH 5.4, 85μL of 0.22M PBS pH
5.4 and 15μL of 0.017% hydrogen peroxide were added to
the wells. The reaction was started by addition of 20μLo fEvidence-Based Complementary and Alternative Medicine 3
18.4mM tetramethylbenzidine HCl in dimethylformamide.
T h ep l a t e sw e r ei n c u b a t e da t3 7 ◦C for 3min and then placed
on ice. The reaction was stopped by the addition of 30μL
of 1.46M sodium acetate, pH 3.0. Enzyme activity was
determined colorimetrically using a plate reader (EL808-
BioTech Instruments, Inc., Winooski, VT, USA) set to
measure absorbance at 630nm and is expressed as mOD mg
per tissue.
2.6. Drugs. The following substances were used: croton oil,
DE, hexadecyltrimethylammonium bromide, tetramethyl-
benzidine, hydrogen peroxide (all from Sigma-Aldrich, St.
Louis, MO, USA), sodium acetate, dimethylformamide,
acetone and absolute ethanol (all from Merck, Darmstadt,
Germany).
2.7. Statistical Analysis. The results are presented as mean ±
SEM with exception of the ID50 values (dose required to
reduce the responses of the treated groups by 50% relative
to the control group), which are reported as geometric
means plus their respective 95% conﬁdence limits. The
statistical signiﬁcance between the groups was assessed by
one-way analysis of variance (ANOVA) followed by a post
hoc Newman-Keuls test. The accepted level of signiﬁcance
for the test was P < .05. All tests were carried out using
GraphPad Software (San Diego, CA, USA).
3. Results
3.1. Averrhoa carambola on Croton Oil-Induced Cutaneous
Inﬂammation. Topical application of croton oil promoted
an increase in the thickness of the ear and in the tissue
MPO activity. Upon application of the ethanolic extract
of Averrhoa or the various fractions of the extract, croton
oil-induced ear edema and cellular migration in mice
were both reduced eﬀectively. As shown in Figure 1(a),
topically applied ethanolic extract from A. carambola (0.03–
1.0mg/ear)resultedinadose-dependentinhibitionofcroton
oil-induced ear edema, with an ID50 value of 0.05 (0.02–
0.13) mg/ear and a maximum inhibition of 78 ± 5%
(at 0.6mg/ear). MPO is a marker of polymorphonuclear
leukocytes. MPO activity is directly related to the amount of
leukocyte inﬁltration, which is indicative of an inﬂammatory
reaction. In order to verify the eﬀectsof the extract on croton
oil-induced cell inﬁltration, MPO activity was assessed.
Ethanolic extract treatment (0.03–1.0mg/ear) promoted a
dose-dependent reduction in enzyme activity (Figure 1(b)).
The maximum inhibition was 61 ± 16% (at 0.6mg/ear),
and the ID50 value was 0.22 (0.08–0.60) mg/ear. In these
tests, treatment with the reference drug, DE (at 0.1mg/ear),
resulted in an inhibition of edema and MPO activity by 89 ±
5a n d7 9± 4%, respectively.
3.2. Activity of Fractions from the Ethanolic Extract of A.
carambola. In view of the results with the extract, we fur-
ther investigated whether its fractions could change these
inﬂammatory parameters. Hex, EtOAc and BuOH fractions
from the ethanolic extract of A. carambola (1.0mg/ear) also
reduced ear edema formation. Treatment resulted in maxi-
muminhibitionvaluesof73±7,75±5and63±14%forthe
Hex, EtOAc and BuOH fractions, respectively (Figure 2(a)).
Figure 2(b) shows the MPO inhibition caused by the A.
carambola fractions (at 1.0 mg/ear). All of the fractions were
able to reduce the croton oil-induced increase in enzyme
activity, with inhibition values of 40 ± 4, 54 ± 8a n d4 2±
11% using the Hex, EtOAc and BuOH fractions, respectively.
Onceagain, DE treatment causedan inhibition of 86 ± 7an d
83 ± 1% of edema and cell migration, respectively.
3.3. Evaluation of Flavonoids Isolated from the A. carambola
Extract. Since the ethanolic extract from A. carambola and
its fractions were eﬀective in reducing the inﬂammatory
parameters, it became interesting to analyze the eﬀects of
topical application of the isolated ﬂavonoids, compounds 1
and 2. As shown in Figure 3(a), topically applied compound
1(1.0mg/ear)didnotalterthecrotonoil-inducedearedema,
while ﬂavonoid 2 caused a mild inhibition (28 ± 11%) at
a dose of 1.0mg/ear. DE inhibited edema by 95 ± 2%.
Among natural compounds, interaction eﬀects are often
observed. In order to determine whether there is a possible
interaction between the isolated compounds, another exper-
iment was performed in which the two compounds were co-
administered. The inhibition of edema formation observed
upon co-administration was 34 ± 11%, which was identical
to the inhibition caused by compound 2 alone. Once again,
DE resulted in an inhibition of 95 ± 2% (Figure 3(b)).
4. Discussion
Acute inﬂammation is characterized by classical symptoms,
such as heat, redness, swelling and pain. Edema (swelling)
is therefore a good measure of inﬂammation and is useful
for the quantiﬁcation of skin inﬂammation induced by
phlogistic agents such as croton oil. Croton oil-induced ear
edema is a widely used method for studying the inﬂamma-
tory process in skin, and for identifying anti-inﬂammatory
agents that could be useful in the treatment of skin disorders
[26, 27].
The present study provides evidence that A. carambola
leaves have a relevant topical anti-inﬂammatory eﬀect in
a model of cutaneous inﬂammation in mice. Here, we
showed that the plant reduced edema and inhibited the
cellular migration of polymorphonuclear leukocytes, an
important step in the inﬂammatory process. Croton oil is a
phlogistic agent extracted from Croton tiglium L., Euphor-
biaceae, and it has an irritant and vesiculant eﬀect on
the skin. Croton oil contains phorbol esters, being the 12-
O-tetradecanoylphorbol-13-acetate (TPA) the predominant
phorbol ester. Topical application of croton oil or TPA
promotes an acute inﬂammatory reaction characterized by
vasodilatation, polymorphonuclear leukocyte inﬁltration to
the tissue and edema formation. These changes are triggered
by protein kinase C (PKC) activation, which promotes an
increase in the activity of phospholipase A2 (PLA2). Activa-
tion of PLA2 results in increased levels of arachidonic acid
and its metabolites, such as prostaglandins and leukotrienes4 Evidence-Based Complementary and Alternative Medicine
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Figure 1:EﬀectofethanolicextractfromA.carambolaandDEtopicallyadministeredoncrotonoil-inducedearedema(a)andMPOactivity
(b). Ear edema and enzymatic activity was measured at 6h and 24h after croton oil treatment, respectively. The extract (0.03–1.0mg/ear)
and DE (0.1mg/ear) were applied after croton oil application. Each bar represents the mean ± SEM for four to ﬁve animals. The graphic
symbols denote the signiﬁcance levels when compared with control groups. Signiﬁcantly diﬀerent from controls, ∗P < .05, ∗∗P < .01, ∗∗∗P <
.001.
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Figure 2: Eﬀe c to ft h ef r a c t i o n so fe t h a n o l i ce x t r a c tf r o mA. carambola and DE administered topically on croton oil-induced ear edema
(a) and MPO activity (b). Ear edema and enzymatic activity was measured at 6 h and 24h after croton oil treatment, respectively. Animals
were challenged with croton oil and so treated with the fractions Hex, EtOAc and BuOH (1.0mg/ear) and DE (0.1mg/ear). Each bar
represents the mean ± SEM for four to ﬁve animals. The graphic symbols denote the signiﬁcance levels when compared with control groups.
Signiﬁcantly diﬀerent from controls, ∗P < .05, ∗∗P < .01, ∗∗∗P < .001.
[24, 27–29]. Moreover, PKC also promotes the secretion and
activation of several immune mediators such as cytokines
and chemokines which increase and maintain the skin in-
ﬂammatory response [30].
The ethanolic extract and its fractions promoted a signif-
icant and dose-dependent inhibition of croton oil-induced
skin inﬂammation. Topically applied croton oil resulted in
activation of pro-inﬂammatory mediators that promoted the
manifestation of several inﬂammatory parameters similar to
some skin disorders [31]. Using this model, compounds that
inhibit this process, such as the ones in A. carambola,c a nb e
target in the search for new therapeutic strategies.
Unlike the ethanolic extract, which showed eﬃcient anti-
edematogenic activity, the isolated ﬂavonoids did not dem-
onstrate pronounced activities toward reducing ear edema.
Compound 2 caused mild inhibition of edema, while com-
pound 1 had no eﬀect. In the ﬁeld of herbal medicine,
interaction of the activities of compounds found in plant
extracts may result in the potentiation of the activity
of each compound by the others. This could explain whyEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of isolated compounds from A. carambola and DE topically administered on croton oil-induced ear edema (a) and the
eﬀect of interaction between the compounds (b). Ear edema was measured at 6h after croton oil treatment. Animals were challenged with
croton oil and so treated with the compounds 1 (apigenin-6-C-β-l-fucopyranoside) and 2 (apigenin-6-C-(-2
  -O-α-l-rhamnopyranosyl)-
β-l-fucopyranoside) (1.0mg/ear) or DE (0.1mg/ear). Each bar represents the mean ± SEM for four to ﬁve animals. The graphic symbols
denote the signiﬁcance levels when compared with control groups. Signiﬁcantly diﬀerent from controls, ∗P < .05, ∗∗∗P < .001.
Leukocyte migration 
oedema formation
Extract of Averrhoa carambola L.
Fractions: Hex; EtOAc and BuOH
Compound: number 2
Figure 4: Proposed eﬀect of A. carambola against croton oil-in-
duced skin responses. Schema represents a cross section of skin
showing its layers—epidermis, dermis and hypodermis, as well as
skin appendages (hair follicle, sudoriferous and sebaceous glands).
Highlights a capillary which after croton oil stimulus promotes
plasma leakage and cell migration, and A. carambola extract,
fractions and compound 2 inhibit both events (cell migration and
edema).
numerous attempts to isolate individual active compounds
from medicinal plants have been unsuccessful [32]. In order
to determine whether there is an interaction between our
two compounds of interest, we evaluated the eﬀects of co-
administering them on inﬂammation. The eﬀect of co-
administering the compounds was not diﬀerent from those
observed upon administration of compound 2 alone. These
results suggest that these compounds are not responsible for
the ethanolic extract anti-inﬂammatory response.
Cellular inﬁltration represents an important feature in
skin inﬂammation, and neutrophils are the predominant
type of cells that inﬁltrate the area. These cells play a crucial
role in cutaneous inﬂammation. Leukocyte accumulation in
theskinisimportantfortheprogressionoftheinﬂammatory
reaction as well as for the increase in expression of some
inﬂammatory enzymes such as cyclooxygenase-2 [33, 34].
MPO is an enzyme known to be a marker of neutrophil
inﬁltration. Thus, inhibition of MPO activity can be used
to indicate the presence of an anti-inﬂammatory reaction
[4, 35]. Topical treatments with the ethanolic extract or its
fractions were able to inhibit MPO activity, indicating that
these compounds may inﬂuence cell migration during the
inﬂammatory process. However, it is too early to propose
a detailed mechanism through which the extract/fractions
exert their anti-inﬂammatory activity. Averrhoa carambola
compounds could be inﬂuencing one or more steps of the
croton oil-induced inﬂammatory cascade, such as protein
kinase C and phospholipase A2 activation, cyclooxygenase-2
induction, and cytokine production and release [26, 27].
Nowadays, the treatment of inﬂammatory skin diseases
is very diﬃcult because these diseases are chronic and need
extended treatment, which can result in the development6 Evidence-Based Complementary and Alternative Medicine
of drug resistance by the patient. The most common treat-
ments used are based on corticosteroids [36], and re-
cently, treatments such as monoclonal antibodies against
immunoglobulin E as efalizumab have been used [37,
38]. However, these treatments are often ineﬀective and/or
accompanied by a series of undesirable side eﬀects [39].
Therefore, research has currently been focused on ﬁnding
eﬀectivemethodstointerferewiththeinﬂammatorycascade.
An eﬀective measure would be the inhibition of nuclear
factor kappa B (NF-κB). This transcription factor regulates
thetranscriptionofimportantpro-inﬂammatorygenes,such
as genes for cytokines, chemokines, adhesion molecules,
COX-2,nitricoxidesynthaseandothers.Thus,theinhibition
of NF-κB prevents the production of these mediators,
resulting in a decrease in the inﬂammatory process [40].
A large group of natural substances has demonstrated
anti-inﬂammatory activity. Among these substances are the
following: ﬂavonoids, tannins, steroids and terpenes, which
are able to interfere with several components of the inﬂam-
matory cascade [41]. As previously shown, A. carambola is
rich in these kinds of compounds, particularly with ﬂavones.
Although the ﬂavonoids evaluated in this study were inef-
fective, it would be interesting to determine the potential
activity of the other compounds from the plant in order to
elucidate the mechanism by which the plant inﬂuences the
inﬂammatory process.
In summary, we have shown that the ethanolic extract
from A. carambola and its BuOH, EtOAc and Hex fractions
are eﬀective in reducing croton oil-induced ear edema and
cellular migration in mice (Figure 4). Although additional
studies are necessary to address the mechanism of action
of A. carambola, our results support the popular use of this
plant for skin inﬂammatory disorders.
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